Comparative study of cathepsin B-cleavable linkers for the optimal design of cathepsin B-specific doxorubicin prodrug nanoparticles for targeted cancer therapy
Authors:
- 15 September 2022
- journal article
- research article
- Published by Elsevier in Biomaterials
- Vol. 289, 121806
Abstract
No abstract availableKeywords
Funding Information
- National Research Foundation of Korea (NRF-2019R1A2C3006283)
This publication has 52 references indexed in Scilit:
- A Target-Specific Oral Formulation of Doxorubicin-Protein Nanoparticles: Efficacy and Safety in Hepatocellular CancerJournal of Cancer, 2013
- Nanoparticles as delivery carriers for anticancer prodrugsExpert Opinion on Drug Delivery, 2012
- Cathepsin B-sensitive nanoprobe for in vivo tumor diagnosisJournal of Materials Chemistry, 2011
- Prodrugs for improving tumor targetability and efficiencyAdvanced Drug Delivery Reviews, 2011
- Factors Affecting the Clearance and Biodistribution of Polymeric NanoparticlesMolecular Pharmaceutics, 2008
- Polymer conjugates as anticancer nanomedicinesNature Reviews Cancer, 2006
- Development of potent monoclonal antibody auristatin conjugates for cancer therapyNature Biotechnology, 2003
- Targeted prodrug design to optimize drug deliveryAAPS PharmSci, 2000
- Prodrugs of anticancer agentsAdvanced Drug Delivery Reviews, 1996
- Amino acid and dipeptide derivatives of daunorubicin. 2. Cellular pharmacology and antitumor activity of L1210 leukemic cells in vitro and in vivoJournal of Medicinal Chemistry, 1980